Market review on Clopidogrel Tablet
Ideal College of Pharmacy, Kalyan, Maharashtra, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(03), 347–356
Article DOI: 10.30574/wjbphs.2024.19.3.0640
Publication history:
Received on 03 August 2024; revised on 11 September 2024; accepted on 14 September 2024
Abstract:
Antiplatelet drugs are drugs which interfere with platelet function and are useful in the prophylaxis of thromboembolic disorders. Clopidogrel is the most commonly used Antiplatelet drug(1). Clopidogrel was first reported in 1987 to be an inhibitor of ADP induced platelet activation. It was first approved by US-FDA in1997 and was developed and manufactured by bristol-myers squibb (BMS) in collaboration with Sanofi-Aventis. Plavix is a patented brand of Clopidogrel and plavix's patent expired in May, 2012. Plavix (clopidogrel) has been the most prescribed antiplatelet brand-name drug for the prevention of heart attack or stroke, and was the second best-selling drug in the world, with $9.4 billion in global sales in 2010(3). After listening to a lot of people's opinion about clopidogrel, it has been noticed that this drug works very well in about 70to 80% of the people. Some people also experience side effect mainly bleeding, headache, stomach and abdominal pain.re
The growing global population of people suffering from cardiovascular illnesses and other disorders is the fundamental reason for the increased demand for clopidogrel. Furthermore, in the next six years, rising economies in the Asia Pacific area are predicted to be the largest consumers of clopidogrel due to changing lifestyles and an increase in the number of patients with cardiovascular illnesses (3). Furthermore, the patentexpiration of the clopidogrel medicine is expected to open the floodgates for various pharmaceutical businesses to enter the clopidogrel drug production business.Recent studies have raised concern that a significantclinical interaction may exist between Clopidogrel and proton pump inhibitors. Studies suggest PPI may diminish Clopidogrels effect (1).
Since the patent expired in 2012 the drug is now available in over 100 different brands and has many generic formulations. According to many pharma experts the demand for this drug is expected to increase in the future due to the increasing incidence of cardiovascular diseases.
After all the drug cropidogrel has become a necessity for many people today considering the deadly disease of stroke and heart attack (2).
Keywords:
Clopidogrel; Patent expiration; Side effects; Necessity
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0